Moreover, patients with high-risk scores were more sensitive to anti-tumor drugs such as Bexarotene, QS11, Pyrimethamine, AKT inhibitor VIII, Imatinib, Cyclopamine, Embelin, Vinorelbine, NSC-87877, GNF-2, and PHA-665752, while patients with low-risk scores were more sensitive to CMK, Z-LLNle-CHO, WZ-1-84, Saracatinib, Dasatinib, JW-7-52-1, WH-4-023, BMS-509744, CGP-60474, TAE684, Paclitaxel, Parthenolide, and XMD8-85. Here, AKT1 is linked to neoplasm.